TAF-test: a tumor diagnosis device in oncologic urology.
A screening test for detecting antibodies to HSV-TAA was performed on 26 sera, from urinary bladder carcinoma patients and on 30 sera from prostatic carcinoma patients. Positive results were found in 50% of the urinary bladder cancer sera and in 60% of the prostatic carcinoma sera. As control 10/11 sera from benign prostatic hypertrophy and 4/4 sera from renal pelvis or ureter neoplasias (tumors never previously associated to HSV) were negative before and after surgery. The only one positive of the former group became negative after surgical treatment. The TAF-test can therefore be a meaningful test for monitoring antibody levels in the sera of patients before, during or after the treatment, in order to evaluate the presence of metastases or the success of a therapy.
D000328:Adult; D000368:Aged; D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis*; D000939:Epitopes / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011470:Prostatic Hyperplasia / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy; D012698:Serologic Tests; D018139:Simplexvirus / Q000276:immunology; D013997:Time Factors; D014412:Tumor Virus Infections / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy; D014571:Urologic Neoplasms / Q000276:immunology* / Q000628:therapy
D000912:Antibodies, Neoplasm; D000939:Epitopes